Wilson Sonsini advised Light Horse Therapeutics, a developer of small molecule therapeutics, on its multi-target collaboration with Novartis to identify and develop therapeutics using the biotech’s proprietary platform. Under the terms of the agreement, announced on January 9, 2025, Light Horse will receive a $25 million upfront payment. The company is also eligible for $1 billion in further research, development, and sales milestones, in addition to royalties on licensed therapeutics. Further details are undisclosed.

The Wilson Sonsini team that advised Light Horse on the transaction includes:

Technology Transactions
Farah Gerdes
Miranda Biven
Sarah (Siedlak) Walker

Corporate
Karen Deschaine
Phil McGill

Patents and Innovations
Lou Lieto

For more information, please see Light Horse's news release. Additional coverage can be found on Fierce Biotech.